PortfoliosLab logoPortfoliosLab logo
TATT vs. BMRN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TATT vs. BMRN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tat Techno (TATT) and BioMarin Pharmaceutical Inc. (BMRN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TATT achieves a -4.12% return, which is significantly higher than BMRN's -8.03% return. Over the past 10 years, TATT has outperformed BMRN with an annualized return of 20.56%, while BMRN has yielded a comparatively lower -4.86% annualized return.


TATT

1D
6.10%
1M
22.48%
YTD
-4.12%
6M
6.49%
1Y
60.71%
3Y*
86.27%
5Y*
49.10%
10Y*
20.56%

BMRN

1D
2.51%
1M
-1.44%
YTD
-8.03%
6M
0.64%
1Y
-3.75%
3Y*
-16.34%
5Y*
-6.84%
10Y*
-4.86%
*Multi-year figures are annualized to reflect compound growth (CAGR)

TATT vs. BMRN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
TATT
Tat Techno
-4.12%73.91%153.00%91.51%-16.00%39.28%-10.30%-17.89%-41.43%23.44%
BMRN
BioMarin Pharmaceutical Inc.
-8.03%-9.58%-31.83%-6.83%17.14%0.75%3.71%-0.70%-4.51%7.64%

Correlation

The correlation between TATT and BMRN is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.08

Correlation (3Y)
Calculated over the trailing 3-year period

0.04

Correlation (5Y)
Calculated over the trailing 5-year period

0.08

Correlation (10Y)
Calculated over the trailing 10-year period

0.08

Correlation (All Time)
Calculated using the full available price history since Jul 27, 1999

0.08

Fundamentals

Market Cap

TATT:

$565.41M

BMRN:

$10.80B

EPS

TATT:

$1.29

BMRN:

$1.37

PE Ratio

TATT:

33.30

BMRN:

39.85

PEG Ratio

TATT:

0.25

BMRN:

2.39

PS Ratio

TATT:

3.09

BMRN:

3.30

PB Ratio

TATT:

3.13

BMRN:

1.74

Total Revenue (TTM)

TATT:

$177.02M

BMRN:

$3.24B

Gross Profit (TTM)

TATT:

$44.18M

BMRN:

$2.46B

EBITDA (TTM)

TATT:

$22.13M

BMRN:

$439.56M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TATT vs. BMRN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TATT
TATT Risk / Return Rank: 6868
Overall Rank
TATT Sharpe Ratio Rank: 7171
Sharpe Ratio Rank
TATT Sortino Ratio Rank: 6767
Sortino Ratio Rank
TATT Omega Ratio Rank: 6767
Omega Ratio Rank
TATT Calmar Ratio Rank: 6666
Calmar Ratio Rank
TATT Martin Ratio Rank: 6868
Martin Ratio Rank

BMRN
BMRN Risk / Return Rank: 3434
Overall Rank
BMRN Sharpe Ratio Rank: 3636
Sharpe Ratio Rank
BMRN Sortino Ratio Rank: 3232
Sortino Ratio Rank
BMRN Omega Ratio Rank: 3232
Omega Ratio Rank
BMRN Calmar Ratio Rank: 3535
Calmar Ratio Rank
BMRN Martin Ratio Rank: 3434
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TATT vs. BMRN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tat Techno (TATT) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


TATTBMRNDifference
Sharpe ratioReturn per unit of total volatility

+1.10

Sortino ratioReturn per unit of downside risk

+1.51

Omega ratioGain probability vs. loss probability

1.21

1.01

+0.20

Calmar ratioReturn relative to maximum drawdown

1.28

-0.17

+1.45

Martin ratioReturn relative to average drawdown

3.41

-0.35

+3.76

TATT vs. BMRN - Sharpe Ratio Comparison

The current TATT Sharpe Ratio is 0.99, which is higher than the BMRN Sharpe Ratio of -0.11. The chart below compares the historical Sharpe Ratios of TATT and BMRN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


TATTBMRNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.99

-0.11

+1.10

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.93

-0.21

+1.14

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.42

-0.14

+0.55

Sharpe Ratio (All Time)

Calculated using the full available price history

0.08

0.11

-0.03

Drawdowns

TATT vs. BMRN - Drawdown Comparison

The maximum TATT drawdown since its inception was -97.07%, which is greater than BMRN's maximum drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for TATT and BMRN.


Loading charts...

Drawdown Indicators


TATTBMRNDifference

Max Drawdown

Largest peak-to-trough decline

-97.07%

-90.58%

-6.49%

Max Drawdown (1Y)

Largest decline over 1 year

-47.50%

-22.49%

-25.01%

Max Drawdown (3Y)

Largest decline over 3 years

-47.50%

-49.83%

+2.33%

Max Drawdown (5Y)

Largest decline over 5 years

-47.50%

-57.64%

+10.14%

Max Drawdown (10Y)

Largest decline over 10 years

-75.11%

-62.09%

-13.02%

Current Drawdown

Current decline from peak

-29.92%

-63.35%

+33.43%

Average Drawdown

Average peak-to-trough decline

-66.05%

-45.51%

-20.54%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.83%

10.84%

+6.99%

Volatility

TATT vs. BMRN - Volatility Comparison

Tat Techno (TATT) has a higher volatility of 25.05% compared to BioMarin Pharmaceutical Inc. (BMRN) at 15.30%. This indicates that TATT's price experiences larger fluctuations and is considered to be riskier than BMRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TATTBMRNDifference

Volatility (1M)

Calculated over the trailing 1-month period

25.05%

15.30%

+9.75%

Volatility (6M)

Calculated over the trailing 6-month period

48.04%

27.79%

+20.25%

Volatility (1Y)

Calculated over the trailing 1-year period

61.66%

34.57%

+27.09%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

52.89%

32.87%

+20.02%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

49.52%

35.51%

+14.01%

Dividends

TATT vs. BMRN - Dividend Comparison

Neither TATT nor BMRN has paid dividends to shareholders.


PositionTTM2025202420232022202120202019201820172016
BMRN
BioMarin Pharmaceutical Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
TATT
Tat Techno
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.24%3.88%

Financials

TATT vs. BMRN - Financials Comparison

This section allows you to compare key financial metrics between Tat Techno and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M20222023202420252026
41.15M
766.21M
(TATT) Total Revenue
(BMRN) Total Revenue
Values in USD except per share items

TATT vs. BMRN - Profitability Comparison

The chart below illustrates the profitability comparison between Tat Techno and BioMarin Pharmaceutical Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%20222023202420252026
24.4%
74.6%
Portfolio components
TATT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Tat Techno reported a gross profit of 10.03M and revenue of 41.15M. Therefore, the gross margin over that period was 24.4%.

BMRN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a gross profit of 571.21M and revenue of 766.21M. Therefore, the gross margin over that period was 74.6%.

TATT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Tat Techno reported an operating income of 2.99M and revenue of 41.15M, resulting in an operating margin of 7.3%.

BMRN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported an operating income of 129.64M and revenue of 766.21M, resulting in an operating margin of 16.9%.

TATT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Tat Techno reported a net income of 3.40M and revenue of 41.15M, resulting in a net margin of 8.3%.

BMRN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BioMarin Pharmaceutical Inc. reported a net income of 105.53M and revenue of 766.21M, resulting in a net margin of 13.8%.


Frequently Asked Questions


TATT and BMRN have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

TATT has higher volatility (25.05%) compared to BMRN (15.30%). In terms of maximum drawdown, TATT dropped -97.07% vs BMRN's -90.58%.

TATT currently has the higher Sharpe Ratio (0.99 vs -0.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TATT and BMRN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer